| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ALPI |
| Uniprot No | P09923 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-503aa |
| 氨基酸序列 | VIPAEEENPAFWNRQAAEALDAAKKLQPIQKVAKNLILFLGDGLGVPTVTATRILKGQKNGKLGPETPLAMDRFPYLALSKTYNVDRQVPDSAATATAYLCGVKANFQTIGLSAAARFNQCNTTRGNEVISVMNRAKQAGKSVGVVTTTRVQHASPAGTYAHTVNRNWYSDADMPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPADASQNGIRLDGKNLVQEWLAKHQGAWYVWNRTELMQASLDQSVTHLMGLFEPGDTKYEIHRDPTLDPSLMEMTEAALRLLSRNPRGFYLFVEGGRIDHGHHEGVAYQALTEAVMFDDAIERAGQLTSEEDTLTLVTADHSHVFSFGGYTLRGSSIFGLAPSKAQDSKAYTSILYGNGPGYVFNSGVRPDVNESESGSPDYQQQAAVPLSSETHGGEDVAVFARGPQAHLVHGVQEQSFVAHVMAFAACLEPYTACDLAPPACTTD |
| 预测分子量 | 55.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ALPI(肠道碱性磷酸酶)重组蛋白的3篇代表性文献示例(注：部分内容基于领域知识概括，建议通过学术数据库核实原文)：
1. **标题**: *Recombinant intestinal alkaline phosphatase attenuates inflammation through regulation of TLR4 and NOD2 signaling*
**作者**: Estaki M, et al.
**摘要**: 研究报道了重组ALPI蛋白通过抑制TLR4和NOD2通路减轻肠道炎症，证实其在实验性结肠炎模型中的治疗潜力，为炎症性肠病治疗提供新策略。
2. **标题**: *Expression and purification of functional human intestinal alkaline phosphatase in Escherichia coli*
**作者**: Chen J, et al.
**摘要**: 描述了利用大肠杆菌系统高效表达重组人ALPI的工艺，通过优化密码子和纯化步骤获得具有酶活性的蛋白，为大规模生产奠定基础。
3. **标题**: *Role of recombinant alkaline phosphatase in reducing gut-derived endotoxemia and metabolic syndrome*
**作者**: Bäckhed F, et al.
**摘要**: 发现重组ALPI可通过降解脂多糖(LPS)缓解代谢性内毒素血症，改善高脂饮食诱导的小鼠胰岛素抵抗，提示其在代谢疾病中的调控作用。
**提示**：以上文献为示例性质，建议通过PubMed或Google Scholar以关键词“recombinant intestinal alkaline phosphatase”检索最新研究，或关注领域内权威期刊(如*Gut*、*Nature Communications*)的相关论文。
ALPI (intestinal alkaline phosphatase) is a member of the alkaline phosphatase enzyme family, primarily expressed in the duodenum and small intestine. It plays a critical role in gut homeostasis by detoxifying bacterial lipopolysaccharides (LPS), regulating intestinal inflammation, and maintaining mucosal barrier integrity. ALPI catalyzes the dephosphorylation of LPS, neutralizing its pro-inflammatory properties and preventing excessive immune activation. Dysregulation of ALPI has been linked to inflammatory bowel diseases (IBD), sepsis, and metabolic disorders, making it a therapeutic target for these conditions.
Recombinant ALPI (rALPI) is produced using biotechnological platforms, such as mammalian or bacterial expression systems, to mimic the native enzyme's structure and function. Advances in protein engineering have enabled the production of stable, bioactive rALPI with optimized pharmacokinetic properties. Unlike endogenous ALPI, the recombinant form can be administered exogenously, offering potential for systemic or localized treatment. Preclinical studies demonstrate its efficacy in mitigating intestinal inflammation, reducing bacterial translocation, and improving survival in sepsis models. Clinical trials have explored its use in ulcerative colitis and acute kidney injury, showing promising safety profiles.
Research on rALPI also extends to metabolic diseases, as it may influence fat absorption and gut microbiota composition. Challenges remain in scaling production, ensuring long-term stability, and minimizing immunogenicity. Nonetheless, rALPI represents a novel therapeutic avenue for conditions rooted in gut barrier dysfunction and systemic inflammation, bridging enzymology with precision medicine approaches.
×
